Go Pro
→ Your 10X AI demo is starting… (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
▼
$0.02
$80K1.5923.72 million shsN/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
$0.42
-8.7%		$2.42
$0.37
▼
$80.00
$180K-0.25492,483 shs1.00 million shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.10
$386K0.13282,029 shs104,100 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,213.79%
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%0.00%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
0.00%-77.53%-84.88%-85.46%-99.43%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%+40.00%-30.00%+16.67%-65.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
▼
$0.02
$80K1.5923.72 million shsN/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
$0.42
-8.7%		$2.42
$0.37
▼
$80.00
$180K-0.25492,483 shs1.00 million shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.10
$386K0.13282,029 shs104,100 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,213.79%
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%0.00%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
0.00%-77.53%-84.88%-85.46%-99.43%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%+40.00%-30.00%+16.67%-65.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00
N/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
0.00
N/AN/AN/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
2.00
HoldN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NVTA, SRNE, AMPE, and SLXN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2026
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/15/2026
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
Invitae Co. stock logo
NVTA
Invitae
$481.58M0.00N/AN/A$0.42 per share0.00
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/AN/AN/AN/A$8.33 per shareN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.01N/AN/AN/A∞
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-$11.91M-$80.50N/AN/AN/AN/A-516.86%-176.68%N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84M-$0.17N/AN/AN/AN/AN/AN/A8/18/2026 (Estimated)

Latest NVTA, SRNE, AMPE, and SLXN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/18/2026N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.42N/AN/AN/A$18.23 millionN/A
8/14/2026Q2 2026
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-$21.20-$5.17+$16.03-$5.17N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
N/A
2.39
2.25
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/A
1.00
1.00
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
Invitae Co. stock logo
NVTA
Invitae
61.28%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
10.95%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%

Insider Ownership

CompanyInsider Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
3.30%
Invitae Co. stock logo
NVTA
Invitae
0.74%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
4.10%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
201.14 million1.10 millionNo Data
Invitae Co. stock logo
NVTA
Invitae
1,700267.01 million284.37 millionNo Data
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/A420,000402,000N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
800551.28 million536.95 millionNo Data

Recent News About These Companies

Sorrento Voyage Announces Expanded Luxury Boat Tours and Proposal Experiences Along the Amalfi Coast
January 5, 2026  |  newsfilecorp.comN
Sorrento Therapeutics Inc (SRNE) - Investing.com
July 3, 2025  |  investing.comhttps://www.investing.com/equities/sorrento-therape-opinion
SRNE Sorrento Therapeutics, Inc. - Seeking Alpha
June 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/SRNE
Sorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | Benzinga
April 19, 2025  |  benzinga.comhttps://www.benzinga.com/quote/SRNE
Sorrento Shareholders Lose Discovery Bid Over Judge Relationship
March 28, 2025  |  news.bloomberglaw.comN
Scilex says bankruptcy court extends lockup period on shares of Scilex dividend
January 31, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scilex-says-bankruptcy-court-extends-lockup-period-on-shares-of-scilex-dividend-1034296170
DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills
October 24, 2024  |  newsfilecorp.comN
Sorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO says
August 20, 2024  |  msn.comhttps://www.msn.com/en-us/health/medical/sorrento-enrols-60-of-80-patient-phase-ii-target-for-abivertinib-in-covid-19-futility-analysis-potentially-in-a-month-ceo-says/ar-AA1p7arP
Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter
May 29, 2024  |  newsfilecorp.comN
Sorrento Therapeutics Inc (SRNE)
May 25, 2024  |  investing.comhttps://www.investing.com/equities/sorrento-therape-opinion/3
Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person
May 8, 2024  |  newsfilecorp.comN
DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing
May 1, 2024  |  newsfilecorp.comN
Sorrento Therapeutics Inc SRNE
April 26, 2024  |  morningstar.comM
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
March 27, 2024  |  news.bloomberglaw.comN
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
March 27, 2024  |  news.bloomberglaw.comN
Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)
March 12, 2024  |  news.bloomberglaw.comN
Judge Declines to Dismiss Sorrento Therapeutics Bankruptcy Case
March 12, 2024  |  wsj.comhttps://www.wsj.com/articles/judge-declines-to-dismiss-sorrento-therapeutics-bankruptcy-case-8321bd69
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
February 27, 2024  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2024/02/27/9968471.htm
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
February 27, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240227926537/en/virpax-pharmaceuticals-announces-proposed-settlement-of-litigation-with-sorrento-therapeutics-inc.-and-scilex-pharmaceuticals-inc./
Sorrento Therapeutics
February 7, 2024  |  pharmaphorum.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ampio Pharmaceuticals stock logo

Ampio Pharmaceuticals NYSE:AMPE

$0.18 0.00 (0.00%)
As of 08/14/2026

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Invitae stock logo

Invitae NYSE:NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Silexion Therapeutics stock logo

Silexion Therapeutics NASDAQ:SLXN

$0.42 -0.04 (-8.65%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$0.41 -0.01 (-3.38%)
As of 08/14/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0007 0.00 (0.00%)
As of 08/14/2026 01:27 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas